F
Francesco E. Pontieri
Researcher at Sapienza University of Rome
Publications - 140
Citations - 8326
Francesco E. Pontieri is an academic researcher from Sapienza University of Rome. The author has contributed to research in topics: Parkinson's disease & Dopaminergic. The author has an hindex of 35, co-authored 128 publications receiving 7542 citations. Previous affiliations of Francesco E. Pontieri include National Institutes of Health & University of Cagliari.
Papers
More filters
Journal ArticleDOI
Changes in neuropeptide FF and NPY immunohistochemical patterns in rat brain under heroin treatment.
TL;DR: Heroin-induced changes in the brain of rats suggest that NPFF is involved in regulating the effects of the heroin injection and in the mechanisms underlying behavioral sensitization and add further support to the key role of NPY in any conditions tending to change the animal homeostasis.
Journal ArticleDOI
DUOGLOBE: One-Year Outcomes in a Real-World Study of Levodopa Carbidopa Intestinal Gel for Parkinson's Disease.
David G. Standaert,Jason Aldred,Marieta Anca-Herschkovitsch,Paul Bourgeois,Esther Cubo,Thomas L. Davis,Robert Iansek,Norbert Kovács,Francesco E. Pontieri,Mustafa S. Siddiqui,Mihaela Simu,Lars Bergmann,Pavnit Kukreja,Weining Z. Robieson,K. Ray Chaudhuri +14 more
TL;DR: Levodopa‐carbidopa intestinal gel (LCIG) is an established treatment for improving motor and some non‐motor symptoms in patients with advanced Parkinson's disease.
Journal ArticleDOI
Increased lymphocyte dopamine β-hydroxylase immunoreactivity in Alzheimer's disease: Compensatory response to cholinergic deficit?
Franco Giubilei,Caterina Calderaro,Giovanni Antonini,Micaela Sepe-Monti,Paolo Tisei,Ercole Brunetti,Francesca Marchione,Brunella Caronti,Francesco E. Pontieri +8 more
TL;DR: This work shows a slight decrease in acetylcholinesterase (AChE) and a significant increase in dopamine β-hydroxylase (DBH) immunoreactivity in the PBL of patients with probable Alzheimer's disease, and hypothesizes that the increase in DBH immunore activity may represent a compensatory response to cholinergic impairment.
Journal ArticleDOI
The impact of extended release dopamine agonists on prescribing patterns for therapy of early Parkinson's disease: an observational study
Clelia Pellicano,Dario Benincasa,Alessandra Fanciulli,Pamela Latino,Morena Giovannelli,Francesco E. Pontieri +5 more
TL;DR: The results suggest that extended release DA might optimize therapeutic management of the early stages of Parkinson’s disease even in patients older than 70 years of age.
Journal ArticleDOI
Yawning in Parkinson's disease
TL;DR: It is well known that apomorphine, a direct D1–D2 dopamine receptor agonist, frequently induces yawning just before the onset of the motor effect, both in experimental animals and in patients with PD.